JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Whole-body MR angiography with body coil acquisition at 3 T in patients with peripheral arterial disease using the contrast agent gadofosveset trisodium.

RATIONALE AND OBJECTIVES: Whole-body magnetic resonance angiography (WB-MRA) at 3 T with body coil acquisition has not previously been investigated. In this study, WB-MRA was performed in this manner using the blood pool contrast agent gadofosveset trisodium.

MATERIALS AND METHODS: Eleven consecutive patients (five men, six women) with symptomatic peripheral arterial disease (two with critical limb ischemia, nine with claudication) were examined. Conventional digital subtraction angiography (DSA) of the aorta and the inflow and runoff arteries was used as the reference method. WB-MRA was performed using four slightly overlapping stations covering the arteries from the neck to the ankles. The arterial system was divided into 42 segments that were analyzed for the presence of significant arterial disease (> or =50% luminal narrowing or occlusion) by two blinded observers.

RESULTS: Sensitivities for detecting a significant arterial lesion with WB-MRA using gadofosveset as the contrast agent were 0.66 (95% confidence interval [CI], 0.49-0.79) and 0.68 (95% CI, 0.52-0.81) for the two observers. Specificities were 0.82 (95% CI, 0.74-0.88) and 0.93 (95% CI, 0.87-0.96), respectively. Intermodality agreement between WB-MRA and DSA was moderate to good, with overall kappa values of 0.44 (95% CI, 0.29-0.59) and 0.63 (95% CI, 0.5-0.77) for the two observers. Interobserver agreement for WB-MRA was good, at kappa = 0.60 (95% CI, 0.50-0.71).

CONCLUSION: WB-MRA at 3 T with body coil acquisition in patients with peripheral arterial disease showed good reproducibility but only moderate to good agreement with DSA. Further assessment of the method's clinical application is warranted.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app